EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study

Yanli Fang iD, Yun Shao, Xinyi Lin, Qihui Xu, Yu Shang, Mingli Chen, Siyi Chen, Yinqiu Lv, Jianna Zhang, Huidi Zhang iD

Journal of Nephrology · 2026

DOI: 10.1093/joneph/aajag094 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Nephrology, 2026. Verfasst von Yanli Fang und 9 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical College, Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Naphthyridines, Sodium-Glucose Transporter 2 Inhibitors, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit nennt 17 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to evaluate the efficacy and safety of finerenone, with or without combination therapy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) or renin-angiotensin system inhibitors (RASi), in Chinese patients with non-diabetic chronic kidney disease (non-diabetic CKD) at different follow-up time points.

Methods

Patients with non-diabetic CKD who received finerenone treatment from March 2023 to August 2025 were retrospectively enrolled. According to the treatment regimens, patients were divided into four groups: finerenone monotherapy group (without SGLT2i or RASi), finerenone + SGLT2i group, finerenone + RASi group, and finerenone + SGLT2i + RASi group. The main evaluated indicators included urine albumin-to-creatinine ratio (UACR), urine protein-to-creatinine ratio (UPCR), serum creatinine (Scr), estimated glomerular filtration rate (eGFR), and serum potassium (K+) levels.

Results

A total of 483 patients were enrolled in this study, including 229 males (47.41%); baseline UACR was 520.1 (interquartile range [IQR], 259.2–993.9) mg/g. After receiving finerenone treatment for 18 months, the UACR decreased by 69.18%. During the study period, the change in eGFR remained stable, with only 2.48% of patients experiencing an eGFR decline >30%. Hyperkalemia occurred in only 6 patients (1.24%), indicating a good safety profile during the medication period.

Conclusion

Finerenone can effectively reduce proteinuria in patients with non-diabetic CKD. Dual or triple combination therapy demonstrated more pronounced effects, with an overall favorable safety profile. Nevertheless, careful monitoring of short-term changes in eGFR and serum K+ levels remains essential during finerenone therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicNaphthyridinesSodium-Glucose Transporter 2 InhibitorsAngiotensin-Converting Enzyme InhibitorsHumansMaleFemaleMiddle AgedDrug Therapy, CombinationRetrospective StudiesGlomerular Filtration RateTreatment OutcomeAgedCreatininePotassiumProteinuria

Stichwörter der Autor:innen

UACReGFRfinerenoneproteinuria

Substanzen

NaphthyridinesSodium-Glucose Transporter 2 InhibitorsfinerenoneAngiotensin-Converting Enzyme InhibitorsCreatininePotassium

Autor:innen und Institutionen

  • First Clinical College, Wenzhou Medical University, Wenzhou, China.
  • Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

ORCID-Profile: Yanli Fang, Huidi Zhang

Förderung

  • Zhejiang Provincial Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Fang, Y., Shao, Y., Lin, X., Xu, Q., Shang, Y., Chen, M., Chen, S., Lv, Y., Zhang, J., & Zhang, H. (2026). Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study. Journal of Nephrology. https://doi.org/10.1093/joneph/aajag094

Vancouver

Fang Y, Shao Y, Lin X, Xu Q, Shang Y, Chen M, et al. Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study. Journal of Nephrology. 2026. doi:10.1093/joneph/aajag094

BibTeX
@article{Fang2026,
  author = {Fang, Yanli and Shao, Yun and Lin, Xinyi and Xu, Qihui and Shang, Yu and Chen, Mingli and Chen, Siyi and Lv, Yinqiu and Zhang, Jianna and Zhang, Huidi},
  title = {Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study},
  journal = {Journal of Nephrology},
  year = {2026},
  doi = {10.1093/joneph/aajag094}
}
Kostenlos starten →